Publications
321
Citations
3,995
Est. group size
—
Recurring co-author estimate
Active years
14
Publishing since 2013
- A phase II trial of cabozantinib in relapsed refractory germ-cell tumors (GCT).
Journal of Clinical Oncology · 2026
- Maintenance zanzalintinib with oral etoposide following high-dose chemotherapy in patients with relapsed metastatic germ-cell tumor (GCT).
Journal of Clinical Oncology · 2026
- Primary Mediastinal Seminoma: Clinical Characteristics and Outcomes
Clinical Genitourinary Cancer · 2026
- First interim analysis of SWOG S1823: Operating characteristics of circulating microRNA 371a-3p (miR371) in predicting active germ cell malignancy (aGCM) in patients (pts) with early-stage testicular cancer.
Journal of Clinical Oncology · 2026
- Early discontinuation of <sup>177</sup> Lu-PSMA-617 after ≤ 3 doses in prostate cancer: A single-center retrospective cohort study.
Journal of Clinical Oncology · 2026
- Clinical and pathological outcomes of patients with germ-cell tumor undergoing surgical resection of residual disease after high-dose chemotherapy.
Journal of Clinical Oncology · 2026
- Clinical characteristics, treatment patterns, and outcomes for patients with germ-cell tumor and brain metastases at diagnosis vs. relapse.
Journal of Clinical Oncology · 2026
- Genomic alterations in metastatic renal cell carcinoma (mRCC): Impact on survival and response to front-line systemic therapy.
Journal of Clinical Oncology · 2026
- Establishing a rapid diagnostic clinic at a tertiary care cancer center: The Indiana University Simon Comprehensive Cancer Center (IUSCCC) experience.
Journal of Clinical Oncology · 2026
- High-dose chemotherapy (HDCT) and peripheral-blood stem-cell transplant (PBSCT) for relapsed seminoma: A single-center cohort.
Journal of Clinical Oncology · 2026
- Expression of nectin-4 in germ-cell tumors.
Journal of Clinical Oncology · 2026
- c-MET expression by IHC and response to cabozantinib in patients with relapsed, refractory germ-cell tumor: A single-arm phase II trial.
Journal of Clinical Oncology · 2026
- Integrated clinical and genomic analysis of mediastinal germ cell tumors (GCT) with somatic transformation (SM): A multi-institutional cohort study.
Journal of Clinical Oncology · 2026
- Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants with cisplatin-ineligible muscle-invasive bladder cancer (MIBC): An analysis of clinically relevant subgroups in KEYNOTE-905.
Journal of Clinical Oncology · 2026
- Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin ineligible: Phase 3 KEYNOTE-905 study.
Journal of Clinical Oncology · 2026
- Journal of Clinical Oncology×134
- The Journal of Urology×13
- Clinical Genitourinary Cancer×11
- Urologic Oncology Seminars and Original Investigations×9
- Annals of Oncology×7
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 9, 2026.
Claim or correct this profile